Eisai Of Japan To Face Alzheimer's Competition As Others Gear Up
This article was originally published in PharmAsia News
Executive SummaryJapan's Eisai could face competition from Daiichi Sankyo and Switzerland's Novartis for drugs to treat Alzheimer's disease
You may also be interested in...
CES 2020: Panel Discusses Health Care In 2040 – Empowered Consumer, Digital Transformation, Data Sharing, Open Source
AveXis President David Lennon talked to Pink Sheet about quality enhancement at the gene therapy unit, a clinical trial hold for Zolgensma in Type 2 SMA, and expansion in gene therapy.
With business heavily dependent on sales revenue from Medicare Part D and other US government programs, Lilly will be expected to narrow the gap between US prescription and sales growth.